Literature DB >> 22621828

Pneumococcal vaccines WHO position paper - 2012 - recommendations.

.   

Abstract

This article presents the World Health Organization (WHO) recommendations on the use of pneumococcal vaccines excerpted from the Pneumococcal vaccines WHO position paper - 2012 recently published in the Weekly Epidemiological Record. The current document replaces the position paper on the use 7-valent pneumococcal conjugate vaccine published in 2007. Incorporating the most recent developments in the field of pneumococcal vaccines this position paper focuses on the currently available 10-valent and 13-valent conjugate vaccines and their introduction and use in national immunization programmes. It also deals with the 23-valent polysaccharide vaccine, though in less detail than provided in the April 2008 position paper which remains valid. Footnotes to this paper provide a number of core references including references to grading tables that assess the quality of scientific evidence for a few key conclusions. In accordance with its mandate to provide guidance to Member States on health policy matters, WHO issues a series of regularly updated position papers on vaccines and combinations of vaccines against diseases that have an international public health impact. These papers are concerned primarily with the use of vaccines in large-scale immunization programmes; they summarize essential background information on diseases and vaccines, and conclude with WHO's current position on the use of vaccines worldwide. This paper reflects the recommendations of the WHO's Strategic Advisory Group of Experts (SAGE) on immunization. Recommendations on the use of pneumococcal vaccines were discussed by SAGE at its meetings in November 2006 (conjugate vaccine) and April 2008 (polysaccharide vaccine) and most recently in November 2011. Evidence presented at these meetings can be accessed at http://www.who.int/immunization/sage/previous/en/index.html.
Copyright © 2012. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22621828     DOI: 10.1016/j.vaccine.2012.04.093

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  74 in total

Review 1.  The potential impact of pneumococcal conjugate vaccine in Africa: Considerations and early lessons learned from the South African experience.

Authors:  Shabir A Madhi; Marta C Nunes
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

2.  Epidemiologic and clinical implications of second-generation pneumococcal conjugate vaccines.

Authors:  Carmen Muñoz-Almagro; Adoracion Navarro-Torne; Roman Pallares
Journal:  Curr Infect Dis Rep       Date:  2013-04       Impact factor: 3.725

3.  Crystallization and preliminary X-ray crystallographic studies of DnaJ from Streptococcus pneumoniae.

Authors:  Shasha Zhao; Li Jin; Siqiang Niu; Wei Yang; Shaocheng Zhang; Zhen Guo; Hongpeng Zhang; Ailong Huang; Yibing Yin; Deqiang Wang
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2013-02-22

4.  Crystallization and preliminary X-ray analysis of RabX3, a tandem GTPase from Entamoeba histolytica.

Authors:  Vijay Kumar Srivastava; Mintu Chandra; Sunando Datta
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2014-06-18       Impact factor: 1.056

Review 5.  Measuring immune responses to pneumococcal vaccines.

Authors:  David C LaFon; Moon H Nahm
Journal:  J Immunol Methods       Date:  2018-08-08       Impact factor: 2.303

Review 6.  Malnutrition and vaccination in developing countries.

Authors:  Andrew J Prendergast
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-06-19       Impact factor: 6.237

Review 7.  Pneumococcal Capsules and Their Types: Past, Present, and Future.

Authors:  K Aaron Geno; Gwendolyn L Gilbert; Joon Young Song; Ian C Skovsted; Keith P Klugman; Christopher Jones; Helle B Konradsen; Moon H Nahm
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

Review 8.  Pneumococcal vaccination among HIV-infected adult patients in the era of combination antiretroviral therapy.

Authors:  Kuan-Yeh Lee; Mao-Song Tsai; Kuang-Che Kuo; Jen-Chih Tsai; Hsin-Yun Sun; Aristine C Cheng; Sui-Yuan Chang; Chen-Hsiang Lee; Chien-Ching Hung
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

9.  Towards the 13-valent pneumococcal conjugate universal vaccination: effectiveness in the transition era between PCV7 and PCV13 in Italy, 2010-2013.

Authors:  Domenico Martinelli; Biagio Pedalino; Maria Giovanna Cappelli; Giovanni Caputi; Anna Sallustio; Francesca Fortunato; Silvio Tafuri; Vanessa Cozza; Cinzia Germinario; Maria Chironna; Rosa Prato
Journal:  Hum Vaccin Immunother       Date:  2013-10-07       Impact factor: 3.452

10.  Viral-bacterial (co-)occurrence in the upper airways and the risk of childhood pneumonia in resource-limited settings.

Authors:  James S Ngocho; Linda Minja; Christa E van der Gaast-de Jongh; Janette C Rahamat-Langendoen; Jeroen D Langereis; Blandina T Mmbaga; Marien I de Jonge
Journal:  J Infect       Date:  2020-06-10       Impact factor: 6.072

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.